These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33540355)

  • 21. Analysis of c-Met kinase domain complexes: a new specific catalytic site receptor model for defining binding modes of ATP-competitive ligands.
    Asses Y; Leroux V; Tairi-Kellou S; Dono R; Maina F; Maigret B
    Chem Biol Drug Des; 2009 Dec; 74(6):560-70. PubMed ID: 19909299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site.
    Fabbro D; Manley PW; Jahnke W; Liebetanz J; Szyttenholm A; Fendrich G; Strauss A; Zhang J; Gray NS; Adrian F; Warmuth M; Pelle X; Grotzfeld R; Berst F; Marzinzik A; Cowan-Jacob SW; Furet P; Mestan J
    Biochim Biophys Acta; 2010 Mar; 1804(3):454-62. PubMed ID: 20152788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sphingosine kinase 1 (SK1) allosteric inhibitors that target the dimerization site.
    Bayraktar O; Ozkirimli E; Ulgen K
    Comput Biol Chem; 2017 Aug; 69():64-76. PubMed ID: 28587987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allosteric Modulation of Src Family Kinases with ATP-Competitive Inhibitors.
    Register AC; Chakraborty S; Maly DJ
    Methods Mol Biol; 2017; 1636():79-89. PubMed ID: 28730474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kinetic characterization and molecular docking of novel allosteric inhibitors of aminoglycoside phosphotransferases.
    Leban N; Kaplan E; Chaloin L; Godreuil S; Lionne C
    Biochim Biophys Acta Gen Subj; 2017 Jan; 1861(1 Pt A):3464-3473. PubMed ID: 27640112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selectively targeting an inactive conformation of interleukin-2-inducible T-cell kinase by allosteric inhibitors.
    Han S; Czerwinski RM; Caspers NL; Limburg DC; Ding W; Wang H; Ohren JF; Rajamohan F; McLellan TJ; Unwalla R; Choi C; Parikh MD; Seth N; Edmonds J; Phillips C; Shakya S; Li X; Spaulding V; Hughes S; Cook A; Robinson C; Mathias JP; Navratilova I; Medley QG; Anderson DR; Kurumbail RG; Aulabaugh A
    Biochem J; 2014 Jun; 460(2):211-22. PubMed ID: 24593284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Affinity purification of proteins binding to kinase inhibitors immobilized on self-assembling monolayers.
    Bantscheff M; Hobson S; Kuster B
    Methods Mol Biol; 2012; 795():149-60. PubMed ID: 21960221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibitors of the herbicidal target IspD: allosteric site binding.
    Witschel MC; Höffken HW; Seet M; Parra L; Mietzner T; Thater F; Niggeweg R; Röhl F; Illarionov B; Rohdich F; Kaiser J; Fischer M; Bacher A; Diederich F
    Angew Chem Int Ed Engl; 2011 Aug; 50(34):7931-5. PubMed ID: 21766403
    [No Abstract]   [Full Text] [Related]  

  • 29. Chemical inhibitors of cyclin-dependent kinases: insights into design from X-ray crystallographic studies.
    Noble ME; Endicott JA
    Pharmacol Ther; 1999; 82(2-3):269-78. PubMed ID: 10454204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural basis of inhibitor selectivity in MAP kinases.
    Wang Z; Canagarajah BJ; Boehm JC; Kassisà S; Cobb MH; Young PR; Abdel-Meguid S; Adams JL; Goldsmith EJ
    Structure; 1998 Sep; 6(9):1117-28. PubMed ID: 9753691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Substrate-Induced Facilitated Dissociation of the Competitive Inhibitor from the Active Site of O-Acetyl Serine Sulfhydrylase Reveals a Competitive-Allostery Mechanism.
    Singh AK; Ekka MK; Kaushik A; Pandya V; Singh RP; Banerjee S; Mittal M; Singh V; Kumaran S
    Biochemistry; 2017 Sep; 56(37):5011-5025. PubMed ID: 28805060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective detection of allosteric phosphatase inhibitors.
    Schneider R; Beumer C; Simard JR; Grütter C; Rauh D
    J Am Chem Soc; 2013 May; 135(18):6838-41. PubMed ID: 23611635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
    Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
    ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of Novel Allosteric Non-Bisphosphonate Inhibitors of Farnesyl Pyrophosphate Synthase by Integrated Lead Finding.
    Marzinzik AL; Amstutz R; Bold G; Bourgier E; Cotesta S; Glickman JF; Götte M; Henry C; Lehmann S; Hartwieg JC; Ofner S; Pellé X; Roddy TP; Rondeau JM; Stauffer F; Stout SJ; Widmer A; Zimmermann J; Zoller T; Jahnke W
    ChemMedChem; 2015 Nov; 10(11):1884-91. PubMed ID: 26381451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of the CHK1 allosteric inhibitor binding site.
    Vanderpool D; Johnson TO; Ping C; Bergqvist S; Alton G; Phonephaly S; Rui E; Luo C; Deng YL; Grant S; Quenzer T; Margosiak S; Register J; Brown E; Ermolieff J
    Biochemistry; 2009 Oct; 48(41):9823-30. PubMed ID: 19743875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A liquid chromatography/mass spectrometry-based method for the selection of ATP competitive kinase inhibitors.
    Khandekar SS; Feng B; Yi T; Chen S; Laping N; Bramson N
    J Biomol Screen; 2005 Aug; 10(5):447-55. PubMed ID: 16093554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-ATP competitive protein kinase inhibitors.
    Garuti L; Roberti M; Bottegoni G
    Curr Med Chem; 2010; 17(25):2804-21. PubMed ID: 20586715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.
    Traxler PM; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Med Chem; 1996 Jun; 39(12):2285-92. PubMed ID: 8691423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systematic assessment of structure-promiscuity relationships between different types of kinase inhibitors.
    Hu H; Bajorath J
    Bioorg Med Chem; 2021 Jul; 41():116226. PubMed ID: 34082305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors.
    Vijayan RS; He P; Modi V; Duong-Ly KC; Ma H; Peterson JR; Dunbrack RL; Levy RM
    J Med Chem; 2015 Jan; 58(1):466-79. PubMed ID: 25478866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.